Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of medications used to treat type 2 diabetes mellitus (T2DM) by blocking the reabsorption of glucose in the kidneys, resulting in increased urinary glucose excretion and improved glycemic control [1]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.